In recent years, bionic collagen technology has achieved significant progress. At the beginning of 2025, Phoenix Regeneration Technology announced that its independently developed product, POGMENT Triple-Helix Bionic Collagen, received national invention patent authorization. Featuring a unique triple-helix biomimetic structure, this innovation represents a breakthrough in both mechanical performance and bioactivity, opening new opportunities for medical aesthetics, biomedical applications, and tissue engineering.

Bionic collagen demonstrates potential advantages over traditional recombinant collagen, particularly in applications such as artificial blood vessels, biomimetic artificial bone, and premium medical aesthetic fillers. Its stability and customizability allow it to address unmet needs across medical devices, skin care, and regenerative medicine.

From a market perspective, traditional recombinant collagen products have seen a decline in supply in recent years, especially Type III humanized collagen, creating space for new entrants. With increasing R&D investment and supportive policy frameworks, the industry is entering a new stage of competition, where patent approvals and product commercialization are set to become critical milestones.

Looking ahead, the growth potential of bionic collagen is closely tied to rising consumer demand. In China, women are experiencing earlier awareness of skin aging, leading to stronger and earlier anti-aging needs. With increasing household income and expanding consumer groups, the bionic collagen industry is expected to accelerate its market penetration and drive long-term growth in both healthcare and beauty sectors.